Related references
Note: Only part of the references are listed.Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib
Kenji Mishiro et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough et al.
CLINICAL CANCER RESEARCH (2021)
Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib
Nicolas Tournier et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2021)
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
Muammar Fawwaz et al.
PHARMACEUTICALS (2021)
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer
Andrea Varrone et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2020)
Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)
Muammar Fawwaz et al.
MOLECULES (2020)
Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
E. A. van de Stadt et al.
EJNMMI RESEARCH (2020)
A Proof-of-Concept Study to Inhibit ABCG2-and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier
Martin Bauer et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Synthesis and preliminary evaluation of 18F-icotinib for EGFR-targeted PET imaging of lung cancer
Xinmiao Lu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
Ayesha Murtuza et al.
CANCER RESEARCH (2019)
Inhibition of ABCB1 and ABCG2 at the Mouse Blood Brain-Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib
Alexander Traxl et al.
MOLECULAR PHARMACEUTICS (2019)
Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer
Marisa L. Martin-Fernandez et al.
CELLS (2019)
PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations
Qiuju Dong et al.
SCIENTIFIC REPORTS (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC
Ofer Shamni et al.
MOLECULAR IMAGING AND BIOLOGY (2019)
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients
Niki Karachaliou et al.
TRANSLATIONAL CANCER RESEARCH (2019)
Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and 11C-Erlotinib PET
Remy B. Verheijen et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Radiosynthesis and biological evaluation of 18F-labeled 4-anilinoquinazoline derivative (18F-FEA-Erlotinib) as a potential EGFR PET agent
Shun Huang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management
Xilin Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Effect of Rifampicin on the Distribution of [11C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice
Martin Bauer et al.
MOLECULAR PHARMACEUTICS (2018)
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
Tomomi Nakamura et al.
PLOS ONE (2018)
Strategies to Inhibit ABCB1-and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates
Nicolas Tournier et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
J. Ryan Petrulli et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
Alexander Traxl et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
18F-Labeled Pyrido[3,4-d]pyrimidine as an Effective Probe for Imaging of L858R Mutant Epidermal Growth Factor Receptor
Hiroyuki Kimura et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
Kentaro Tanaka et al.
Oncotarget (2017)
Development and Evaluation of 18F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC
Yan Song et al.
SCIENTIFIC REPORTS (2017)
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The Rotation Model
Endang R. Purba et al.
CELLS (2017)
11C-PD153035 PET/CT for molecular imaging of EGFR in patients with non-small cell lung cancer (NSCLC)
J. M. Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Predictive efficacy of 11C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients
Dong Dai et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Evaluation of 18F-labeled icotinib derivatives as potential PET agents for tumor imaging
Hongyu Ren et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
Idris Bahce et al.
EJNMMI RESEARCH (2016)
Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor
Paul A. Dickinson et al.
DRUG METABOLISM AND DISPOSITION (2016)
Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib
Alexander Traxl et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
Jianchun Duan et al.
THORACIC CANCER (2015)
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice
Paul Slobbe et al.
EJNMMI RESEARCH (2015)
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET
Galith Abourbeh et al.
EJNMMI RESEARCH (2015)
Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors
Paul Slobbe et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
Idris Bahce et al.
CLINICAL CANCER RESEARCH (2013)
A Pilot Study on EGFR-Targeted Molecular Imaging of PET/CT With 11C-PD153035 in Human Gliomas
Jikui Sun et al.
CLINICAL NUCLEAR MEDICINE (2013)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K. Gan et al.
FEBS JOURNAL (2013)
Metabolism of Epidermal Growth Factor Receptor Targeting Probe [11C]PD153035: Impact on Biodistribution and Tumor Uptake in Rats
Erik Samen et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR Kinase Using PET with [124I]-Morpholino-IPQA
Skye Hsin-Hsien Yeh et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain
J. Ryan Petrulli et al.
NEOPLASIA (2013)
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Flavio Solca et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
A. A. Memon et al.
BRITISH JOURNAL OF CANCER (2011)
Molecular Imaging with 11C-PD153035 PET/CT Predicts Survival in Non-Small Cell Lung Cancer Treated with EGFR-TKI: A Pilot Study
Xue Meng et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor
Britta Weber et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Radiosynthesis and Initial In Vitro Evaluation of [18F]F-PEG6-IPQA-A Novel PET Radiotracer for Imaging EGFR Expression-Activity in Lung Carcinomas
Ashutosh Pal et al.
MOLECULAR IMAGING AND BIOLOGY (2011)
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT
Hsin Hsien Yeh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Tetsuya Mitsudomi et al.
FEBS JOURNAL (2010)
[C-11]Gefitinib ([C-11]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma
Ming-Rong Zhang et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET
Maria A. Pantaleo et al.
MOLECULAR IMAGING AND BIOLOGY (2010)
Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts
Ashfaque A. Memon et al.
CANCER RESEARCH (2009)
Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents
Samar Dissoki et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2009)
PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor-Selective Tracer 11C-PD153035 in Humans
Ningbo Liu et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes
David J. Waxman et al.
MOLECULAR PHARMACOLOGY (2009)
In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [11C]gefitinib
Kazunori Kawamura et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
Evaluation of [F-18]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
Helen Su et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Anesthesia and other considerations for in vivo imaging of small animals
Isabel J. Hildebrandt et al.
ILAR JOURNAL (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety -: An EGFR Putative irreversible inhibitor
Samar Dissoki et al.
APPLIED RADIATION AND ISOTOPES (2007)
Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression
Hui Wang et al.
CANCER SCIENCE (2007)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Further characterization of the epidermal growth factor receptor ligand 11C-PD153035
Wang Hui et al.
CHINESE MEDICAL JOURNAL (2007)
TheEGF receptor family: spearheading a merger of signaling and therapeutics
Erez M. Bublil et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors
Galith Abourbeh et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
The tyrosine kinase inhibitor PD153035:: implication of labeling position on radiometabolites formed in vitro
Erik Samen et al.
NUCLEAR MEDICINE AND BIOLOGY (2006)
Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography
A. Pal et al.
MOLECULAR IMAGING AND BIOLOGY (2006)
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers
J Ling et al.
DRUG METABOLISM AND DISPOSITION (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors
E Mishani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?
AP Dei Tos et al.
EUROPEAN JOURNAL OF CANCER (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man
D McKillop et al.
XENOBIOTICA (2004)
Labeled EGFr-TK irreversible inhibitor (ML03):: In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug
G Ortu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family
PC Bishop et al.
ONCOGENE (2002)
Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
AJ Barker et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001)
Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase
TA Bonasera et al.
NUCLEAR MEDICINE AND BIOLOGY (2001)
The epidermal growth factor receptor as a target for cancer therapy
J Mendelsohn
ENDOCRINE-RELATED CANCER (2001)
Share Paper
